Stieb Sonja, Mohamed Abdallah S R, Deshpande Tanaya S, Harp Jared, Greiner Benjamin, Garden Adam S, Goepfert Ryan P, Cardoso Richard, Ferrarotto Renata, Phan Jack, Reddy Jay P, Morrison William H, Rosenthal David I, Frank Steven J, Fuller C David, Brandon Gunn G
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States.
Clin Transl Radiat Oncol. 2020 Mar 24;22:98-105. doi: 10.1016/j.ctro.2020.03.006. eCollection 2020 May.
Taste impairment is a common radiation-induced toxicity in head and neck cancer (HNC) patients acutely. However, data on the potential for recovery and the time dependent course of late taste impairment are limited.
As part of an IRB-approved observational prospective study, HNC patients underwent serial surveys including the MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN). For our analysis, we extracted MDASI-HN taste item results from oropharyngeal cancer patients treated with intensity-modulated radiotherapy or volumetric modulated arc therapy and at least two taste assessments after ≥1 year from end of radiotherapy (RT).
1214 MDASI taste items from 326 patients between 1 and 13 years post-RT were included. Median prescribed dose to the high-dose clinical target volume (CTV1) was 66.0 Gy, with 180 patients (55%) receiving chemotherapy. Taste markedly improved in the first years from end of RT, but plateaued after year 5. In patients with taste assessment in subsequent years, a significant reduction in taste impairment was found from the second to the third year (p = 0.001) and tended towards significance from the third to the fourth year (p = 0.058). Multivariate analysis revealed treatment site as significant factor in the sixth year from RT and CTV1 dose and age in the seventh year.
Radiation-induced taste impairment may improve over an extended time interval, but becomes relatively stable from year 5 post-RT. Direct characterization of RT-induced taste impairment and the calculation of normal tissue complication probability should include consideration of the time-dependent course in taste recovery.
味觉障碍是头颈部癌(HNC)患者急性放疗常见的毒性反应。然而,关于味觉恢复潜力及晚期味觉障碍随时间变化过程的数据有限。
作为一项经机构审查委员会批准的观察性前瞻性研究的一部分,HNC患者接受了包括MD安德森症状问卷-头颈部模块(MDASI-HN)在内的系列调查。为进行分析,我们从接受调强放疗或容积调强弧形放疗的口咽癌患者中提取了MDASI-HN味觉项目结果,并在放疗结束(RT)≥1年后进行了至少两次味觉评估。
纳入了326例患者放疗后1至13年的1214项MDASI味觉项目。高剂量临床靶区(CTV1)的中位处方剂量为66.0 Gy,180例患者(55%)接受了化疗。从放疗结束后的头几年味觉明显改善,但在第5年后趋于平稳。在随后几年进行味觉评估的患者中,发现从第二年到第三年味觉障碍显著减轻(p = 0.001),从第三年到第四年有减轻趋势(p = 0.058)。多因素分析显示,放疗后第6年治疗部位是显著因素,第7年CTV1剂量和年龄是显著因素。
放疗引起的味觉障碍可能在较长时间内改善,但在放疗后第5年开始相对稳定。对放疗引起的味觉障碍进行直接特征描述和正常组织并发症概率计算时,应考虑味觉恢复的时间依赖性过程。